SAN JOSE, Calif., Oct. 10, 2019 /PRNewswire/ -- Anixa Biosciences,
Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing
the body's immune system to fight cancer, today announced the
appointment of Ian H. Frazer, MD,
AC, FRS, FAA, to its Scientific Advisory Board.
Dr. Frazer is a leading immunologist recognized as one of the
first scientists to study the link between immunity to human
papillomavirus (HPV) infection and cervical cancer. His research
began more than 25 years ago when he and his colleague, the late
Jian Zhou, MD, co-invented a
technology for virus-like particles that trigger an immune response
against HPV. This breakthrough became the basis of two approved
cancer vaccines, Gardasil® and Cervarix®. These two vaccines are
highly effective in protecting against HPV associated infection
which is known to be the cause of cervical and other cancers.
"We are honored to have such a distinguished scientist join our
Scientific Advisory Board," stated Amit
Kumar, PhD, President and Chief Executive Officer of Anixa
Biosciences. "Dr. Frazer's discoveries have enabled us to believe,
with effective global vaccination, that the world can rid itself of
cervical cancer. With his unique knowledge of vaccine technology,
Dr. Frazer joins us at an opportune time, as we have expanded our
therapeutic portfolio with a prophylactic cancer vaccine that has
the potential to eliminate certain types of breast cancer."
"I look forward to working with the Anixa team," commented Dr.
Frazer. "The vaccine technology invented at the Cleveland Clinic is
an exciting approach to prophylactic (preventive) vaccination. I am
excited to lend my experience and expertise to enable testing this
novel immunological approach in humans."
About Ian H. Frazer, MD, AC,
FRS, FAA
Dr. Ian Frazer is a
professor at the University of
Queensland where he leads a research team working at the
Translational Research Institute (TRI) in Brisbane, Australia on the immunobiology of
epithelial cancers. Additionally, he currently serves as the
President of the Australian Academy of Health and Medical Sciences,
and as a member of the Australian National Health and Medical
Research Council. He also chairs the Australian Medical Research
Advisory Board of the Medical Research Future Fund. In addition to
his positions in science and academia, Dr. Frazer serves on the
boards of several corporations and not-for-profit organizations,
including Jingang Medicine (Aus) Pty
Ltd., Microba Pty Ltd and the Frazer Family Foundation. Among his
numerous accolades, Dr. Frazer was recognized as Australian of the
Year in 2006. He was recipient of the Prime Ministers Prize for
Science and the Balzan Prize, both in 2008, followed in 2012 by his
election as a Fellow of the Royal Society of London. He was appointed Companion of the
Order of Australia in 2013. Dr.
Frazer is a named inventor on patents relating to HPV prophylactic
and therapeutic vaccines licenced to CSL, Merck & Co. and
GlaxoSmithKline (GSK), and on patents on DNA vaccines and on
optimizing therapeutic protein expression licensed to Jingang Medicine (Aus) Pty Ltd.
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company focused on harnessing the
body's immune system in the fight against cancer. Anixa's
therapeutic portfolio includes a cancer vaccine technology focused
on the immunization against α-Lactalbumin to prevent triple
negative breast cancer (TNBC), as well as a cancer immunotherapy
program which uses a novel type of CAR-T, known as chimeric
endocrine receptor T-cell (CER-T) technology. The company's
diagnostic portfolio consists of Cchek™, a liquid biopsy technology
for early detection of solid tumors based on the body's immune
response to the presence of a malignancy. Anixa continually
examines emerging technologies in complementary fields for further
development and commercialization. Additional information is
available at www.anixa.com.
Forward-Looking Statements: Statements
that are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not statements
of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We generally use
the words "believes," "expects," "intends," "plans," "anticipates,"
"likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We
undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You are
cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
release.
Anixa contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
Tiberend Strategic Advisors, Inc.
Sharen Tilman (Investors)
stilman@tiberend.com
646-604-5149
Johanna Bennett (Media)
jbennett@tiberend.com
212-375-2686
View original
content:http://www.prnewswire.com/news-releases/anixa-biosciences-names-cancer-vaccine-pioneer-dr-ian-h-frazer-to-scientific-advisory-board-300935071.html
SOURCE Anixa Biosciences, Inc.